Movement Alert｜BeiGene Rises 3.49% in Regular Trading, Brukinsa Phase 3 Positive Data and Insurance Policy Catalysts Sustain Momentum

Market Focus07-03

On July 3, BeiGene rose 3.49% in regular trading, trading at HK$182.1/share, with turnover of HK$130 million.

The rally was driven by continued market enthusiasm over Brukinsa (zanubrutinib) Phase 3 MANGROVE study results disclosed on June 30. The study evaluated Brukinsa plus rituximab versus bendamustine-rituximab for first-line treatment of mantle cell lymphoma, achieving its primary endpoint with a 43% reduction in disease progression or death risk (HR=0.57). The company plans regulatory submissions in the second half of the year.

Additionally, the national medical insurance directory initial review pass rate reached 92%, coupled with the launch of a commercial insurance innovative drug directory mechanism, further optimizing payment channels for innovative drugs. Brokerages including CITIC Construction Investment expressed bullish views on innovative drug companies benefiting from expanded insurance access.

The broader biotechnology sector rallied in tandem, with 3SBio up 5.07%, Remegen up 4.31%, SKB Bio up 3.46%, and Akeso up 3.22%, providing sector-wide support. The prior CNY 446 million tax supplementary payment overhang has been largely absorbed by the market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190102571?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190102571","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BeiGene Rises 3.49% in Regular Trading, Brukinsa Phase 3 Positive Data and Insurance Policy Catalysts Sustain Momentum","media":"Market Focus","content":"<p><p>On July 3, BeiGene rose 3.49% in regular trading, trading at HK$182.1/share, with turnover of HK$130 million.</p><p>The rally was driven by continued market enthusiasm over Brukinsa (zanubrutinib) Phase 3 MANGROVE study results disclosed on June 30. The study evaluated Brukinsa plus rituximab versus bendamustine-rituximab for first-line treatment of mantle cell lymphoma, achieving its primary endpoint with a 43% reduction in disease progression or death risk (HR=0.57). The company plans regulatory submissions in the second half of the year.</p><p>Additionally, the national medical insurance directory initial review pass rate reached 92%, coupled with the launch of a commercial insurance innovative drug directory mechanism, further optimizing payment channels for innovative drugs. Brokerages including CITIC Construction Investment expressed bullish views on innovative drug companies benefiting from expanded insurance access.</p><p>The broader biotechnology sector rallied in tandem, with 3SBio up 5.07%, Remegen up 4.31%, SKB Bio up 3.46%, and Akeso up 3.22%, providing sector-wide support. The prior CNY 446 million tax supplementary payment overhang has been largely absorbed by the market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeiGene Rises 3.49% in Regular Trading, Brukinsa Phase 3 Positive Data and Insurance Policy Catalysts Sustain Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeiGene Rises 3.49% in Regular Trading, Brukinsa Phase 3 Positive Data and Insurance Policy Catalysts Sustain Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-03 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 3, BeiGene rose 3.49% in regular trading, trading at HK$182.1/share, with turnover of HK$130 million.</p><p>The rally was driven by continued market enthusiasm over Brukinsa (zanubrutinib) Phase 3 MANGROVE study results disclosed on June 30. The study evaluated Brukinsa plus rituximab versus bendamustine-rituximab for first-line treatment of mantle cell lymphoma, achieving its primary endpoint with a 43% reduction in disease progression or death risk (HR=0.57). The company plans regulatory submissions in the second half of the year.</p><p>Additionally, the national medical insurance directory initial review pass rate reached 92%, coupled with the launch of a commercial insurance innovative drug directory mechanism, further optimizing payment channels for innovative drugs. Brokerages including CITIC Construction Investment expressed bullish views on innovative drug companies benefiting from expanded insurance access.</p><p>The broader biotechnology sector rallied in tandem, with 3SBio up 5.07%, Remegen up 4.31%, SKB Bio up 3.46%, and Akeso up 3.22%, providing sector-wide support. The prior CNY 446 million tax supplementary payment overhang has been largely absorbed by the market.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1190102571","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190102571","pubTimestamp":1783042997,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 3, BeiGene rose 3.49% in regular trading, trading at HK$182.1/share, with turnover of HK$130 million.The rally was driven by continued market enthusiasm over Brukinsa (zanubrutinib) Phase 3...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"动向提示|百济神州常规交易涨3.49%Brukinsa第三期利好数据和保单催化剂维持动能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On July 3, BeiGene rose 3.49% in regular trading, trading at HK$182.1/share, with turnover of HK$130 million.The rally was driven by continued market enthusiasm over Brukinsa (zanubrutinib) Phase 3 MANGROVE study results disclosed on June 30. The study evaluated Brukinsa plus rituximab versus bendamustine-rituximab for first-line treatment of mantle cell lymphoma, achieving its primary endpoint with a 43% reduction in disease progression or death risk (HR=0.57). The company plans regulatory submissions in the second half of the year.Additionally, the national medical insurance directory initial review pass rate reached 92%, coupled with the launch of a commercial insurance innovative drug directory mechanism, further optimizing payment channels for innovative drugs. Brokerages including CITIC Construction Investment expressed bullish views on innovative drug companies benefiting from expanded insurance access.The broader biotechnology sector rallied in tandem, with 3SBio up 5.07%, Remegen up 4.31%, SKB Bio up 3.46%, and Akeso up 3.22%, providing sector-wide support. The prior CNY 446 million tax supplementary payment overhang has been largely absorbed by the market.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190102571","isCrawlerRequest":true}